摘要
目的观察急性心肌梗死经瑞替普酶治疗的临床效果。方法选取我院2012-2014年期间收治的64例心肌梗死患者并随机分为观察组与对照组（各32例）,两组患者均在基础药物治疗的基础上分别给予瑞替普酶和尿激酶治疗。结果观察组血管再通率（93.7%）明显优于对照组（75.0%）,两组间差异显著（P〈0.05）,而观察组与对照组之间不良反应率无明显差异（P〉0.05）。结论瑞替普酶治疗急性心肌梗死效果显著。
Objective To observe clinical effect on reteplase for acute myocardial infarction. Methods 64 patients with myocardial infarction from 2012 to 2014 in our hospital were randomly selected into observation group（n=32） and control group（n=32）, patients of two groups were given reteplase and urokinase therapy on the basis of primary drug treatment. Results The recanalization rate（93.7%） in the observation group was significantly better than the control group（75.0%）（P〈0.05）, there was no significant difference of adverse reaction rate between the two groups（P〈0.05）. Conclusion The clinical effect of reteplase for acute myocardial infarction is obvious.
出处
《中国继续医学教育》
2015年第7期228-229,共2页
China Continuing Medical Education
关键词
瑞替普酶
急性心肌梗死
尿激酶
Reteplase
Acute myocardial infarction
Urokinase
